LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Human natural regulatory CD4(+) T cells comprise 5-10% of peripheral CD4(+)T cells. They constitutively express the IL-2Ralpha-chain (CD25) and the nuclear transcription Foxp3. These cells are heterogeneous and contain discrete subsets with distinct phenotypes and functions. Studies in mice report that LAG-3 has a complex role in T cell homeostasis and is expressed in CD4(+)CD25(+) T regulatory cells. In this study, we explored the expression of LAG-3 in human CD4(+) T cells and found that LAG-3 identifies a discrete subset of CD4(+)CD25(high)Foxp3(+) T cells. This CD4(+)CD25(high)Foxp3(+)LAG-3(+) population is preferentially expanded in the PBMCs of patients with cancer, in lymphocytes of tumor-invaded lymph nodes and in lymphocytes infiltrating visceral metastasis. Ex vivo analysis showed that CD4(+)CD25(high)Foxp3(+)LAG-3(+) T cells are functionally active cells that release the immunosuppressive cytokines IL-10 and TGF-beta1, but not IL-2. An in vitro suppression assay using CD4(+)CD25(high)LAG-3(+) T cells sorted from in vitro expanded CD4(+)CD25(high) regulatory T cells showed that this subset of cells is endowed with potent suppressor activity that requires cell-to-cell contact. Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, LAG3 can positively induce Treg cell activation and stimulate its immunosuppressive function [325, 326].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [326]
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Baecher-Allan, C., Brown, J. A., Freeman, G. J., & Hafler, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1245 · Cited by 1,859
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255 · cited 1×
“Natural Treg cells, upon TCR engagement (15, 16), exert their immunosuppressive functions in a contact-dependent fashion.”
BackgroundInterleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173 · cited 1×
“Two subsets of induced Treg cells have been described and are shown to also exist in humans: Tr1 cells, which secrete high levels of IL-10 and arise from CD4 T cells upon encountering Ags in a tolerogenic environment (1), and Th3 cells, which are induced by oral Ag administration and secrete high levels of TGF-b1 (2).”
Background
Cited by
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
“Lag-3+FoxP3+ Treg cells have been shown to be expanded in the PBMC, tumor-infiltrated lymph node, and tumor tissue of both melanoma and colorectal cancer patients (Camisaschi et al., 2010).”
BackgroundRegulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue, Y., & Nishikawa, H. (2019) · Cancer Science · doi:10.1111/cas.14069 · Cited by 1,041
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
“These LAG3+ Tregs display a terminal-effector (CD45RA+CCR7–) phenotype, and proliferate less than their LAG3-negative counterparts (83).”
BackgroundFibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Wang, J., Sanmamed, M. F., Datar, I., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 871
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Gagliani, N., Magnani, C. F., Huber, S., Gianolini, M. E., Pala, M., Licona-Limon, P., Guo, B., Herbert, D. R., Bulfone, A., Trentini, F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3179 · Cited by 793
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
LAG-3: from molecular functions to clinical applications
Maruhashi, T., Sugiura, D., Okazaki, I.-M., & Okazaki, T. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001014 · Cited by 459
“92 93 Such LAG-3-expressing T reg cells produce high levels of immunoregulatory cytokines IL-10 and TGF-β and suppress tumor-specific T cells.”
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
“Besides, tumor-infiltrating Foxp3+LAG-3+Tregs secrete a higher level of immunosuppressive cytokines IL-10 and transforming growth factor-β (TGF-β) to collectively magnify Tregs activity [63, 64].”
BackgroundLim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
NK Cell-Based Immune Checkpoint Inhibition
Khan, M., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 356
Roncarolo, M. G., Gregori, S., Bacchetta, R., Battaglia, M., & Gagliani, N. (2018) · Immunity · doi:10.1016/j.immuni.2018.12.001 · Cited by 355
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Goldberg, M. V., & Drake, C. G. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_114 · Cited by 337
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
“In addition, LAG-3 enhances the immunomodulatory function of Tregs through cytokine- and contact-dependent mechanisms within the tumor (100).”
BackgroundTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Immune checkpoint inhibitors in cancer therapy: a focus on T‐regulatory cells
Sasidharan Nair, V., & Elkord, E. (2018) · Immunology & Cell Biology · doi:10.1111/imcb.1003 · Cited by 298
“The LAG-3 Tregs can produce higher levels of immunosuppressive cytokines such as IL-10 and TGF-b and show effector-memory phenotype (CD45RA CCR7 ) with less proliferation than that of their LAG-3 counterparts.(93) Another study in patients with CRC reported that a unique population of CD4FOXP3 CD25LAG-3 T cells produc…”
BackgroundThe PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function
Pompura, S. L., & Dominguez-Villar, M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mir0817-349r · Cited by 288
Jie, H.-B., Gildener-Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.645 · Cited by 286
“For LAG-3, no significant expression was found among CD4þ TIL subsets, but LAG-3 was predominantly expressed by CD4þCD25hi PBL subsets (Supplementary Figure 1B), consistent with previous report that LAG-3 predominates on CD4þCD25hiFOXP3þ Treg in PBL (Camisaschi et al, 2010).”
ResultMolecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
Kim, H. R., Ha, S.-J., Hong, M. H., Heo, S. J., Koh, Y. W., Choi, E. C., Kim, E. K., Pyo, K. H., Jung, I., Seo, D., et al. (2016) · Scientific Reports · doi:10.1038/srep36956 · Cited by 256
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Hemon, P., Jean-Louis, F., Ramgolam, K., Brignone, C., Viguier, M., Bachelez, H., Triebel, F., Charron, D., Aoudjit, F., Al-Daccak, R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002050 · Cited by 252
“The MHC II ligand LAG-3 molecule plays a key role in the regulation of T cell functioning, and several subsets of LAG-3– expressing T cells are expanded in PBMCs of advanced tumorbearing patients and at tumor sites (12, 26, 40).”
BackgroundMethodResultT Regulatory Cells and Priming the Suppressive Tumor Microenvironment
Paluskievicz, C. M., Cao, X., Abdi, R., Zheng, P., Liu, Y., & Bromberg, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02453 · Cited by 251
“When LAG-3+ Treg and CD4+CD25- T cells are separated via membrane, Treg suppressive capabilities are abrogated indicating that the mechanism required direct cell contact (96).”
BackgroundNatural and Induced T Regulatory Cells in Cancer
Adeegbe, D. O., & Nishikawa, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00190 · Cited by 248
“This study analyzed the frequency and phenotype of Foxp3+ cells in melanoma and colorectal cancer patients at different stages of disease and discovered that increased percentages of LAG-3-expressing Foxp3+ Treg cells preferentially expanded in the peripheral blood and tumor sites raising the notion that these cells r…”
BackgroundImmune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Treg-mediated acquired resistance to immune checkpoint inhibitors
Saleh, R., & Elkord, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.003 · Cited by 236
Tr1 Cells and the Counter-Regulation of Immunity: Natural Mechanisms and Therapeutic Applications
Roncarolo, M. G., Gregori, S., Bacchetta, R., & Battaglia, M. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-662-43492-5_3 · Cited by 229
“However, LAG-3 is also expressed by FOXP3+ Tregs (Huang et al. 2004; Camisaschi et al. 2010), and it is required for the optimal regulatory function of FOXP3+ Tregs (Huang et al.”
BackgroundBurugu, S., Asleh-Aburaya, K., & Nielsen, T. O. (2017) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 222
Kumar, P., Bhattacharya, P., & Prabhakar, B. S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.007 · Cited by 216
“CD4+CD25hiFoxp3+LAG3+ Tregs from PBMCs, tumor invaded lymph nodes and visceral metastatic tissues of melanoma and CRC patients showed preferential proliferation and produced higher amounts of immunosuppressive cytokines such as IL-10 and TGF-β, and also exerted potent suppressive activities in contact-dependent assays…”
BackgroundChocarro, L., Blanco, E., Zuazo, M., Arasanz, H., Bocanegra, A., Fernández-Rubio, L., Morente, P., Fernández-Hinojal, G., Echaide, M., Garnica, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105282 · Cited by 216
Current Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
Bauché, D., Joyce-Shaikh, B., Jain, R., Grein, J., Ku, K. S., Blumenschein, W. M., Ganal-Vonarburg, S. C., Wilson, D. C., McClanahan, T. K., Malefyt, R. D. W., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.007 · Cited by 202
Tregs: Where We Are and What Comes Next?
Zhao, H., Liao, X., & Kang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01578 · Cited by 196
“Specially, in the setting of advanced cancer, LAG-3 is preferentially expressed on tumor-infiltrating Tregs (149) and these Tregs display a terminal effector phenotype and proliferate less than LAG3− Tregs (150).”
BackgroundModulation of regulatory T cell function and stability by co-inhibitory receptors
Lucca, L. E., & Dominguez-Villar, M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 189
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
Shi, A.-P., Tang, X.-Y., Xiong, Y.-L., Zheng, K.-F., Liu, Y.-J., Shi, X.-G., Lv, Y., Jiang, T., Ma, N., & Zhao, J.-B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785091 · Cited by 185
Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
He, Y., Rivard, C. J., Rozeboom, L., Yu, H., Ellison, K., Kowalewski, A., Zhou, C., & Hirsch, F. R. (2016) · Cancer Science · doi:10.1111/cas.12986 · Cited by 185
Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo
Durham, N. M., Nirschl, C. J., Jackson, C. M., Elias, J., Kochel, C. M., Anders, R. A., & Drake, C. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109080 · Cited by 178
“WT or LAG-3 KO responders (5E4 cells) were mixed with FOXP3/GFP+ Tregs for a ratio of 1:1, 1:2, and 1:4 Treg:Tresp.”
ResultInfluentialHuo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176
Naturally occurring regulatory T cells: markers, mechanisms, and manipulation
Schmetterer, K. G., Neunkirchner, A., & Pickl, W. F. (2012) · The FASEB Journal · doi:10.1096/fj.11-193672 · Cited by 173
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
“In intratumoral Tregs, LAG3 is expressed at a higher level than in Tregs found in peripheral or normal tissue.(415,416) Multiple LAG3-modulating candidates have been developed, including LAG3-inhibiting antibody and LAG3 fusion protein.”
BackgroundThe Cellular and Molecular Mechanisms of Immuno-Suppression by Human Type 1 Regulatory T Cells
Gregori, S., Goudy, K. S., & Roncarolo, M. G. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00030 · Cited by 161
“associated with FOXP3+ Treg (Camisaschi et al., 2010), making LAG-3 an undependable marker for distinguishing Tr1 cells from other Treg subsets.”
BackgroundToor, S. M., Murshed, K., Al-Dhaheri, M., Khawar, M., Abu Nada, M., & Elkord, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02936 · Cited by 158
Treg(s) in Cancer: Friends or Foe?
Wolf, D., Sopper, S., Pircher, A., Gastl, G., & Wolf, A. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25016 · Cited by 151
Morgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 157
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 153
Tian, X., Zhang, A., Qiu, C., Wang, W., Yang, Y. Z., Qiu, C., Liu, A., Zhu, L., Yuan, S., Hu, H., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402176 · Cited by 164
Wang, Q., Zhang, J., Tu, H., Liang, D., Chang, D. W., Ye, Y., & Wu, X. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0810-y · Cited by 162
Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD
Tindemans, I., Joosse, M. E., & Samsom, J. N. (2020) · Cells · doi:10.3390/cells9010110 · Cited by 163
Novel targets for immune-checkpoint inhibition in cancer
Borgeaud, M., Sandoval, J. L., Obéid, M., Banna, G. L., Michielin, O. A., Addeo, A., & Friedlaender, A. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102614 · Cited by 159
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
“At the initial stages of cancer development, macrophages in the TME demon- strate the classically activated or M1‐like phenotype with robust antitumor activity, producing proinflammatory cytokines such as IL‐1β, IL‐6, IL‐12, IL‐23, and TNF‐α.45 However, at later stages when TME is enriched with growth factors and anti…”
BackgroundInfluentialJoller, N., & Kuchroo, V. K. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_62 · Cited by 133
“In Tregs, IL-10 is almost exclusively found within the Tim-3+, Lag-3+, and TIGIT+ Treg subsets and TIGIT ligation is able to directly induce IL-10 production in Tregs (Sakuishi et al. 2013; Camisaschi et al. 2010; Joller et al. 2014).”
BackgroundResultLecocq, Q., Keyaerts, M., Devoogdt, N., & Breckpot, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010075 · Cited by 133
The role of regulatory T cells in cancer immunology
Whiteside, T. L. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s55415 · Cited by 148
“However, Treg, especially those present in the TME, are known to express a variety of the same regulatory molecules.(24,25) Therefore, it has been suggested that in addition to blocking negative signaling in Teff, the checkpoint blockade with, for example, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) Abs also eli…”
BackgroundDutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 153
Resolving the identity myth: Key markers of functional CD4+FoxP3+ regulatory T cells
Chen, X., & Oppenheim, J. J. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.05.018 · Cited by 126
“Although LAG3+ Tregs present in tumor patients express IL-10 and TGFβ, they differ from classic Tr1 or Th3 cells, because their inhibitory activity is cell contact-dependent and IL-10- and TGFβ-independent [87].”
BackgroundImmune Checkpoint Inhibition in Head and Neck Cancer
Forster, M. D., & Devlin, M.-J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00310 · Cited by 135
Regulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 159
The CD4-like molecule LAG-3, biology and therapeutic applications
Sierro, S., Romero, P., & Speiser, D. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712598.2011.540563 · Cited by 115
“This subpopulation is expanded in the blood and at the tumor site in patients with advanced cancers [27].”
BackgroundBlocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression
Kawano, Y., Zavidij, O., Park, J., Moschetta, M., Kokubun, K., Mouhieddine, T. H., Manier, S., Mishima, Y., Murakami, N., Bustoros, M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci88169 · Cited by 115
“Spanningtree progression analysis of density-normalized events (SPADE), as depicted in Figure 2B, revealed a significant increase in LAG3 expression on BM Tregs expressing PD1 and/or TIM3; LAG3 has been shown to be a marker of Tregs expanding at the tumor site (25).”
MethodMaeda, T. K., Sugiura, D., Okazaki, I., Maruhashi, T., & Okazaki, T. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007455 · Cited by 129
T regulatory cells in cancer: recent advances and therapeutic potential
Elkord, E., Alcantar-Orozco, E., Dovedi, S. J., Tran, D. Q., Hawkins, R. E., & Gilham, D. E. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.529126 · Cited by 123
“A recent study has shown that LAG-3 identifies a discrete subset of CD4CD25FoxP3 Tregs, which are preferentially expanded in peripheral blood and at tumor sites of cancer patients [54].”
BackgroundNew emerging targets in cancer immunotherapy: the role of LAG3
Puhr, H. C., & Ilhan‐Mutlu, A. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000482 · Cited by 130
“Furthermore, LAG3 expression was found not only in tissue infiltrating lymphocytes but also in peripheral Tregs, tumour involved lymph nodes and within the tumour tissue itself, in melanoma and colon carcinoma.(29) In patients with head and neck squamous cell carcinoma and non-small cell lung cancer, LAG3 was expresse…”
BackgroundSaleh, R., Toor, S. M., Khalaf, S., & Elkord, E. (2019) · Vaccines · doi:10.3390/vaccines7040149 · Cited by 125
Clinical Insights Into Novel Immune Checkpoint Inhibitors
Lee, J. B., Ha, S.-J., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 112
“Biomarker analysis was performed in MSS CRC refractory to immunotherapy; the patients who responded to these agents with a partial response (PR) or stable disease (SD) had increased treatment-associated IFN-γ gene signature scores (Bendell et al., 2020).”
BackgroundInfluentialTumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 136
The Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells
Brummelman, J., Pilipow, K., & Lugli, E. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.007 · Cited by 130
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
de, M. M., Kumar, R., Rivera, F. D. L., Amante, F. H., Sheel, M., Faleiro, R. J., Bunn, P. T., Best, S. E., Beattie, L., Ng, S. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.015 · Cited by 111
“…levels of cellular immune responses, including antigen processing, production of cytokines, and various anti-microbial products (Saraiva and O’Garra, 2010), as well as the expression of inhibitory receptors such as PD-1, TIM-3, and LAG-3 (Camisaschi et al., 2010; Ha et al., 2008; Jin et al., 2010).”
BackgroundInfluentialSaleh, R., Toor, S. M., Nair, V. S., & Elkord, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01469 · Cited by 121
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy
O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 110
Camisaschi, C., Filippo, A. D., Beretta, V., Vergani, B., Villa, A., Vergani, E., Santinami, M., Cabras, A. D., Arienti, F., Triebel, F., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.29 · Cited by 104
Solinas, C., Migliori, E., Silva, P. D., & Willard-Gallo, K. E. (2019) · Cancers · doi:10.3390/cancers11081213 · Cited by 102
“These LAG3+ Tregs have an activated, immunosuppressive phenotype and produce high levels of IL-10 and TGFβ1 [66].”
BackgroundRevilla, S. A., Kranenburg, O., & Coffer, P. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903564 · Cited by 116
“In CRC patients, LAG-3+ Treg cells have been identified in both TILs and in peripheral blood (165).”
BackgroundZhai, W., Zhou, X., Wang, H., Li, W., Chen, G., Sui, X., Li, G., Qi, Y., & Gao, Y. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.005 · Cited by 96
Fcγ receptors and immunomodulatory antibodies in cancer
Gálvez‐Cancino, F., Simpson, A. P., Costoya, C., Matos, I. G., Qian, D., Peggs, K. S., Litchfield, K., & Quezada, S. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00637-8 · Cited by 104
Immune checkpoint molecules in pregnancy: Focus on regulatory T cells
Zhang, Y., & Sun, H. (2020) · European Journal of Immunology · doi:10.1002/eji.201948382 · Cited by 98
Induced regulatory T cells in inhibitory microenvironments created by cancer
Whiteside, T. L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.927432 · Cited by 90
“A number of such regulatory molecules have been identified, including CTLA-4, PD-1, LAG-3 and TIM-3 [95-98].”
BackgroundBeyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 99
“These Tregs exert their suppressive effects selectively in tumor-invaded lymph nodes and lymphocytes infiltrating visceral or cutaneous metastases [30,31].”
BackgroundTumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
Park, H. J., Kusnadi, A., Lee, E.-J., Kim, W. W., Cho, B. C., Lee, I. J., Seong, J., & Ha, S.-J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.001 · Cited by 90
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
Park, K., Veena, M. S., & Shin, D. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830208 · Cited by 98
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Sauer, N. J., Szlasa, W., Jonderko, L., Oślizło, M., Kunachowicz, D., Kulbacka, J., & Karłowicz-Bodalska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179958 · Cited by 93
“al, which proved that LAG-3 defines an active subset of CD4+CD25highFoxp3+ regulatory T cells whose frequency is increased in cancer patients and is spread at tumor sites [49].”
BackgroundImmune Checkpoint Modulation in Colorectal Cancer: What’s New and What to Expect
Jacobs, J., Smits, E., Lardon, F., Pauwels, P., & Deschoolmeester, V. (2015) · Journal of Immunology Research · doi:10.1155/2015/158038 · Cited by 94
LAG3 is not expressed in human and murine neurons and does not modulate α‐synucleinopathies
Emmenegger, M., Cecco, E. D., Hruška-Plocháň, M., Eninger, T., Schneider, M. M., Barth, M., Tantardini, E., Rossi, P. D., Bacioglu, M., Langston, R. G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114745 · Cited by 83
“LAG3 is 45 expressed in activated T cells, natural killer cells and dendritic cells (Triebel et al., 1990; Huard et al., 1994, 1997; Hannier and Triebel, 1999; Workman et al., 2002, 2009; Maçon-Lemaître and Triebel, 2005; Camisaschi et al., 2010), and these findings support its role in the immune system.”
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Archilla‐Ortega, A., Domuro, C., Martín-Liberal, J., & Muñoz, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02264-x · Cited by 84
Centuori, S. M., Trad, M., LaCasse, C. J., Alizadeh, D., Larmonier, C. B., Hanke, N. T., Kartchner, J., Janikashvili, N., Bonnotte, B., Larmonier, N., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0911465 · Cited by 80
“Multiple populations of immunosuppressive T cells have been described in the past 15 years, including the CD4 CD25 subset expressing the transcription factor FoxP3 [20, 21].”
BackgroundBurova, E., Hermann, A., Dai, J., Ullman, E., Halász, G., Potocky, T. B., Hong, S., Liu, M., Allbritton, O., Woodruff, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1376 · Cited by 89
Ménétrier‐Caux, C., Curiel, T. J., Faget, J., Manuel, M., Caux, C., & Zou, W. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0208-y · Cited by 95
“patients [29].”
Control of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 86
CD8+ T cell exhaustion in the tumor microenvironment of breast cancer
Xie, H., Xi, X., Lei, T., Liu, H., & Xia, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1507283 · Cited by 86
Fortunato, O., Borzi, C., Milione, M., Centonze, G., Conte, D., Boeri, M., Verri, C., Moro, M., Facchinetti, F., Andriani, F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31988 · Cited by 83
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Alrasheed, N., Lee, L., Ghorani, E., Henry, J. Y., Conde, L., Chin, M., Galas-Filipowicz, D., Furness, A. J. S., Chavda, S. J., Richards, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1714 · Cited by 74
“Previous work has confirmed the suppressive function of Tregs from BM of patients with multiple myeloma (31, 32), while expression levels of these checkpoint proteins is reported to associate with Treg suppressive function in other cancers (25, 26, 33).”
BackgroundFilipazzi, P., Pilla, L., Mariani, L., Patuzzo, R., Castelli, C., Camisaschi, C., Maurichi, A., Cova, A., Rigamonti, G., Giardino, F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1516 · Cited by 78
“We previously reported that regulatory T cells (Tregs) expressing LAG-3, which potentiates immune suppressive activity, also accumulate in the peripheral blood and tumor lesions of metastatic melanoma patients (6).”
BackgroundImmune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy
Kodumudi, K. N., Siegel, J., Weber, A. M., Scott, E., Sarnaik, A. A., & Pilon-Thomas, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153053 · Cited by 74
“These cells have been shown to be highly suppressive and expanded in tumor sites [31].”
BackgroundTumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
Qin, Y., Zheng, X., Gao, W., Wang, B., & Wu, Y. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.011 · Cited by 96
Emerging Immunotherapy for Acute Myeloid Leukemia
Tabata, R., Chi, S., Yuda, J., & Minami, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041944 · Cited by 83
“Notably, CD4-positive/CD25-high/Foxp3-positive/LAG-3-positive T cells were preferentially expanded in patients with cancer [43].”
BackgroundCutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Chocarro, L., Bocanegra, A., Blanco, E., Fernández, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Piñeiro‐Hermida, S., Vera, R., et al. (2022) · Cells · doi:10.3390/cells11152351 · Cited by 77
The functional and prognostic implications of regulatory T cells in colorectal carcinoma.
Zhang, X., Kelaria, S., Kerstetter, J. C., & Wang, J. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.017 · Cited by 81
“Besides Foxp3, there are other surface markers have been found expressed on Tregs, including CTLA-4 (14), LAG3 (15), GITR (16), HLA-DR (17), ICOS (18), and CD127 (19).”
BackgroundEmerging roles of regulatory T cells in tumour progression and metastasis
Halvorsen, E. C., Mahmoud, S., & Bennewith, K. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9529-x · Cited by 80
“Mechanisms of Treg contact-dependent suppression include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [107], programmed death-ligand 1 (PD-L1) [108, 106], lymphocyte-activation gene 3 (LAG-3) [109], neuropilin 1 (Nrp1) [110] and CD39/73 [105] expression.”
Metadata
- Authors
- Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C.
- Affiliations
- Unit of Immunotherapy of Human Tumors
- Immutep S.A., Faculté de Pharmacie , Chatenay-Malabry,
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Corresponding author
- Camisaschi, Chiara
- Casati, Chiara
- Rini, Francesca
- Perego, Michela
- Parmiani, Giorgio
- Rivoltini, Licia
- Castelli, Chiara
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-01
- Volume
- 184
- Issue
- 11
- Pages
- 6545-6551
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147968481
- Cited by
- 350
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 30 · 2023: 21 · 2022: 46 · 2021: 36 · 2020: 35 · 2019: 29 · 2018: 22 · 2017: 16 · 2016: 17 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- LAG-3, regulatory T cells, Foxp3, CD4+CD25high T cells, tumor-infiltrating lymphocytes, metastasis, immunosuppression, IL-10, TGF-β1, suppressor activity, cell-cell contact, tumor immunology, T cell subsets
- MeSH terms
- Lymphocyte Activation Gene 3 Protein, Cell Separation, Flow Cytometry, Humans, Lymphocyte Activation, Neoplasms, Antigens, CD, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.